Whitfield Advises Zymeworks on Acquisition of Theravance
Overview
Zymeworks agreed to acquire Theravance Biopharma for approximately $929 million in cash, according to the source announcement about the biotech combination.
Offer terms
The agreed consideration was $17 per share, subject to adjustments. Both boards reportedly approved the proposed transaction unanimously.
Portfolio addition
The source identifies YUPELRI, a nebulized COPD maintenance treatment, as an asset that would join Zymeworks' partnered product portfolio.
Closing status
Completion was expected in the second half of 2026 following regulatory and shareholder approvals. The published statement records an agreement rather than confirmation that those conditions had been satisfied.
